In a move that has significant implications for the pharmaceutical industry, the Centers for Medicare & Medicaid Services (CMS) in the United States announced on Monday that it will soon unveil a list of 15 prescription drugs eligible for price negotiations under the Medicare program. This initiative is part of a broader effort to bring down drug costs for millions of American seniors and other Medicare beneficiaries.
